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Abstract
Frequent treatment of the growth-restricted (IUGR) ovine fetus with intra-amniotic IGF-1 increases fetal growth. We aimed
to determine whether increased growth was maintained with an extended dosing interval and to examine possible
mechanisms. Pregnant ewes were allocated to three groups: Control, and two IUGR groups (induced by placental
embolization) treated with weekly intra-amniotic injections of either saline (IUGR) or 360 mg IGF-1 (IGF1). IUGR fetuses were
hypoxic, hyperuremic, hypoglycemic, and grew more slowly than controls. Placental glucose uptake and SLC2A1 (GLUT2)
mRNA levels decreased in IUGR fetuses, but SLC2A3 (GLUT3) and SLC2A4 (GLUT4) levels were unaffected. IGF-1 treatment
increased fetal growth rate, did not alter uterine blood flow or placental glucose uptake, and increased placental SLC2A1
and SLC2A4 (but not SLC2A3) mRNA levels compared with saline-treated IUGR animals. Following IGF-1 treatment, placental
mRNA levels of isoforms of the system A, y
+, and L amino acid transporters increased 1.3 to 5.0 fold, while the ratio of
phosphorylated-mTOR to total mTOR also tended to increase. Weekly intra-amniotic IGF-1 treatment provides a promising
avenue for intra-uterine treatment of IUGR babies, and may act via increased fetal substrate supply, up-regulating placental
transporters for neutral, cationic, and branched-chain amino acids, possibly via increased activation of the mTOR pathway.
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Introduction
Intrauterine growth restriction (IUGR) is associated with
increased perinatal morbidity and mortality [1] and with increased
risk of adult diseases such as diabetes, hypertension, and coronary
artery disease [2]. Impaired growth may persist during childhood
despite optimum nutrition [3].
Although a poorly growing fetus can be relatively easily
identified by obstetric ultrasound, the therapeutic options are
limited. Thus, sustained poor growth in utero frequently results in
the fetus being delivered [4], with the attendant morbidity and
mortality of preterm birth. Further, preterm birth is itself
associated with hypertension [5], diabetes and insulin resistance
[6], ischemic heart disease and stroke [7] in later life.
It is unclear whether intervention early in postnatal life can
ameliorate these increased risks. For example, accelerated post-
natal growth may increase the long-term risks associated with
reduced size at birth [8,9]. Therefore, attempting to reverse IUGR
in utero may represent the optimum approach [10].
In developed nations, IUGR typically is caused by placental
insufficiency, resulting in a reduced fetal nutrient supply [10].
Thus, clinical attempts to improve fetal growth by maternal
supplementation with protein [11] or oxygen [12] were unsuccess-
ful. Attempts to increase placental blood flow with sildenafil citrate
in IUGR ovine pregnancies resulted in adverse outcome [13], and
supplementation of pregnant women carrying severely IUGR
fetuses with L-arginine (a nitric oxide precursor) had no effect on
fetal growth [14]. Therefore, a treatment that bypasses the
placenta may provide the most promising approach.
Insulin-like growth factor-1 (IGF-1) is the primary endocrine
regulator of fetal growth in late gestation. Birth weight is positively
associated with IGF-1 concentrations in umbilical cord blood, and
circulating fetal IGF-1 concentrations are lower in IUGR
pregnancies [15]. Acute high-dose intravenous IGF-1 infusion
has anabolic effects on fetal sheep, stimulating substrate uptake
and inhibiting protein breakdown [16]. However, while continu-
ous vascular access to the fetus is not practicable in IUGR
treatment, the amniotic fluid compartment is routinely accessed in
clinical practice.
IGF-1 administered into the amniotic fluid in sheep is
swallowed and taken up across the fetal gut to circulate intact in
the fetus [17]. Further, administration of low dose intra-amniotic
IGF-1 thrice weekly increases growth of ovine fetuses with IUGR
induced by placental embolization [18]. However, for intra-
amniotic IGF-1 treatment to be clinically useful, a less frequent
administration is required. In addition, circulating fetal concen-
trations of IGF-1 following treatment were either unaltered [18] or
actually decreased [19], with down-regulation of fetal hepatic igf1
mRNA levels [20]. These data suggest that the increased fetal
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directly by circulating IGF-1.
One possible mechanism is via effects on placental nutrient
transport. Glucose is transported across the placenta by facilitated
diffusion, mediated by glucose transporters (members of the
SLC2A family). SLC2A1 and SLC2A3 are the major glucose
transporter isoforms in the placenta of ruminants and rodents [21],
with SLC2A4 also described in humans and rats [22,23]. In
contrast, amino acids are transported across the placenta by active
transport mediated by numerous different amino acid transporters,
many of which have several isoforms [24]. Recent studies have
suggested that changes in placental amino acid transport, possibly
mediated by altered activity of mammalian target of rapamycin
(mTOR), precede growth restriction and may therefore directly
contribute to decreased fetal growth [25]. IGF-1 is known to alter
activity and/or expression of nutrient transporters in different
placental preparations [26,27].
This study aimed to determine whether intra-amniotic IGF-1
administration only once a week would still enhance growth of
IUGR fetuses. We also aimed to identify possible mechanisms of
action by examining the effects of treatment on placental nutrient
transporters and mTOR, and on placental and fetal nutrient
uptake.
Materials and Methods
Ethics statement
Experiments were approved by the University of Auckland
Animal Ethics Committee (approval number AEC/04/2004/
R369).
FAM / VIC: fluorescent reporter dyes bound to the TaqMan
probe. MGBNFQ = molecular-groove binding non-fluorescence
quencher.
Animals
Romney ewes carrying singleton fetuses were acclimatized to
indoor conditions, housed in individual cages with free access to
water and pelleted food. Ewes were randomized to one of three
experimental groups: Control, and two groups of embolized
fetuses subsequently treated with saline (IUGR) or IGF-1 (IGF1).
Ewes were fasted overnight before surgery under halothane
general anesthesia at 98 days gestational age (dGA) (term =147
dGA). Catheters were placed in both fetal femoral arteries (FA)
and veins (FV) via the tarsal vessels, and the common umbilical
vein (UV) [28]. Two amniotic catheters were inserted into the
amniotic sac. Growth catheters were inserted around each side of
the fetal chest from the sternum to the spine to measure changes in
fetal girth [29]. Catheters were also placed in the maternal femoral
artery (MA) and vein, the carotid artery and jugular vein and the
utero-ovarian vein (UOV) draining the pregnant horn. In animals
randomized to the IUGR groups, catheters were inserted into both
uterine arteries [30].
Control animals received no embolization and no treatment. In
embolized groups, IUGR was induced between 103 and 109 dGA
by utero-placental embolization with 20–50 mm polystyrene
microspheres (Superose 12, Pharmacia Biotech, Uppasala, Swe-
den) as described previously [19]. IUGR fetuses received intra-
amniotic injections on 110, 117 and 124 dGA of either 360 mg
(100 mg/mL) IGF-1 (Genentech Inc, San Francisco, CA, USA)
(IGF1 group) or an equivalent volume of sterile saline (IUGR
group).
Sampling
Blood and amniotic fluid samples from FA, MA, UV, UOV and
amniotic catheters were taken twice-weekly in the morning before
feeding, and before intra-amniotic injection. Samples were placed
on ice prior to centrifugation, and the supernatants stored at
280uC until assay. Further aliquots of whole blood were
immediately frozen for antipyrine assay and radiotracer counting.
For blood gas analysis (Chiron M845 blood gas analyser; Chiron
Corp., Emeryville, USA), separate blood samples were collected in
heparinized syringes on ice, and analysed within 15 min.
At 120 dGA, the steady-state uterine and fetal uptakes of
glucose, oxygen and lactate, and the placental clearance of non-
metabolizable tracer analogues of glucose (3-O-[methyl
3H]glu-
cose) and urea ([
14C]urea) were assessed using the Fick principle. A
tracer solution comprising 160 mg antipyrine, 500 mCi 3-O-
[Me
3H]glucose and 250 mCi [
14C]urea in 20 ml saline was infused
into a fetal vein for 3.5 h at 3 ml/h following a 4 ml bolus. Under
these conditions antipyrine reaches steady state after 90 min, and
tracers after 2.5 h [30]. From 2.5 h after the start of infusions, five
sets of blood samples, consisting of blood withdrawn simulta-
neously from the FA, UV, MA and UOV, were collected at
15 min intervals.
At 131 dGA ewes were killed with an overdose of pentobar-
bitone. The fetus was dried, weighed and measured. The uterus,
placenta and fetal organs were dissected and weighed. As soon as
the fetus was removed from the uterus, three type B placentomes
were randomly selected and removed, weighed, and snap frozen in
liquid nitrogen and stored at 280uC until analysis.
Hormone and metabolite assays
Glucose, lactate, and urea concentrations were measured on an
autoanalyser (Hitachi 902, Tokyo, Japan) using commercial kits
(glucose and urea, Roche, Mannheim, Germany; lactate, Randox
Laboratories Ltd, Ardmore, UK). IGF-1 was measured by
radioimmunoassay [31]. Progesterone and cortisol concentrations
were measured using mass spectrometry [32].
Antipyrine [33] and amino acid concentrations [34] were
measured by HPLC as described previously, but with a Phenom-
enex Luna column (Luna 3 mm C18(2) 100 A ˚), dimensions
25064.6 mm (Phenomenex, Torrance, USA) for amino acid
analyses. 3-O-[Me
3H]glucose and [
14C]urea specific activities
were measured in duplicate as described previously [35].
Real time PCR
Total RNA was extracted using TRIZOLH (Invitrogen,
Carlsbad, CA, USA). RNA concentration was measured using
a NanoDrop ND-1000 spectrophotometer running 3.1.2 Nano-
Drop software (BioLab Ltd, Auckland, New Zealand). Absorbance
ratios used were 260/280 and 260/230, with ratios $1.9
considered acceptable purity. First-strand cDNA was synthesized
using Superscript III first strand synthesis system (Invitrogen).
Total RNA (5 mg) samples were treated with RNase-free DNase I
(Invitrogen) before reverse transcriptase polymerase chain reaction
(RT-PCR) to eliminate potential genomic DNA.
The target genes using cDNA of placental origin included
SLC2A1 (GLUT-1), SLC2A3 (GLUT-3), SLC2A4 (GLUT-4),
SLC38A4 (system A amino acid transporter isoform ATA-3),
SLC7A1 (system y+ isoform CAT-1), SLC7A5 and SLC7A8 (system
L isoforms LAT-1 & LAT-2), and mTOR. Transcript abundance
was determined by real time PCR TaqMan Gene Expression
Assays (Applied Biosystems, Foster City, CA, USA) on an ABI
Prism 7900HT Sequence Detector (Applied Biosystems) using
cycling conditions recommended by the manufacturer. Singleplex
amplification was carried out in triplicate in 384-well plates with
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Universal PCR Master Mix (Applied Biosystems), 1 ml cDNA
sample, 200 nM probe, 900 nM forward and reverse primers and
6 ml DEPC-treated water. The cDNA samples were diluted 100-
fold for all genes apart from 18S (1,000-fold), mTOR (10-fold),
and SLC38A4 (undiluted). Standard curves for both the target gene
and housekeeping genes, consisting of 10-fold serial dilutions (2-
fold serial dilutions for SLC38A4) of cDNA derived from a single
placental sample, were included in each plate.
Table 1. Primer and probe sequences and characteristics.
Gene and Genbank
(Accession ID)
Primers and
Probes Sequences
Melting
Temperature (uC)
Location on Gene
Sequence (base pairs)
SLC2A1 Forward 59-TCC CAG TGG CCC AAG GA-39 60 1202–1218
(U89029) Reverse 59-GAT CTA TCA GTT TGA GAG TCT CAT CCA-39 58 1239–1265
Probe 6FAM-TCA GAG CGC AGG CAG-MGBNFQ 1223–1237
SLC2A3 Forward 59-TGC CTT ATG GGA TTC TGC AAA-39 59 431–451
(NM_001009770) Reverse 59-TCA GTC GGC CCA AAA TCA G-39 58 473–491
Probe 6FAM-AGC AGA GTC AGT TGA AAT-MGBNFQ 454–471
SLC2A4 Forward 59-AAC CCA GCA CAG AAC TGG AGT AC-39 59 71–93
(AB005283) Reverse 59-CCT GTG TGG ACC CTC AGT CA-39 58 110–130
Probe 59-AGGGCCGGATGAGA-39 96–109
SLC38A4 Forward 59-TTG TTT ACA CTG AAG GAG CTT GTG T-39 59 211–235
(XM_605868) Reverse 59-CAG TTC CAT GGG ATC CAT TTG-39 58 260–280
Probe 6FAM-CAG CGC TTT CTT GTC C-MGBNFQ 238–253
SLC7A1 Forward 59-CCT AGC GCT CCT GGT CAT CA-39 60 271–290
(AF212146) Reverse 59-GGC GTC CTT GCC AAG TAC A-39 58 307–325
Probe 6FAM-CCT TCT GCA TGG CAG C-MGBNFQ 291–306
SLC7A5 Forward 59-CTC CAT CCT CTC CAT GAT CCA-39 58 125–145
(AY162432) Reverse 59-TGT GAA CAC CAG TGA GGG TAC AG-39 59 163–185
Probe 6FAM-CCG CGG CTG CTG A-MGBNFQ 147–159
SLC7A8 Forward 59-GTC AGA GCC CGT GGT GTG T-39 58 205–223
(AY162433) Reverse 59-TGC CAG TAA ATA CCC AGG AAG TAG A-39 59 261–285
Probe 6FAM-CCA TCA TGG TGA CAG GG-MGBNFQ 237–253
mTOR Forward 59-CTG CAC GTC AGC ACC ATC A-39 59 3772–3790
(XM_001788228) Reverse 59-AGC CAT TCC AAC CAA TCA TCT T-39 58 3830–3851
Probe 6FAM-CCT CCA AAA GGC C-MGBNFQ 3792–3804
Cyclophilin A Forward 59- GTA CTG GTG GCA AGT CCA TCT -39 105–125
(AY251270.1) Reverse 59- CAG GAC CTG TAT GCT TCA GAA TGA -39 153–176
Probe 6FAM- ATG GCG AGA AAT TTG-MGBNFQ 126–140
Beta actin Forward 59- ACC AGT TCG CCA TGG ATG ATG -39 76–96
(NM_001009784.1) Reverse 59- CCG GAG CCG TTG TCA AC -39 113–128
Probe 6FAM- ACG AGC GCA GCA ATA T –MGBNFQ 97–112
GAPDH Forward 59- GGG CTG CTT TTA ATA CTG GCA AA -39 91–114
(NM_001190390) Reverse 59- CAT GTA GAC CAT GTA GTG AAG GTC AA -39 146–171
Probe 6FAM- CAT CGT TGC CAT CAA TG –MGBNFQ 120–136
YWHAZ Forward 59- GAG GGT CGT CTC CAG TAT TGA G -39 25–46
(AY970970.1) Reverse 59- TTC TCG AGC CAT CTG CTG TTT T -39 70–91
Probe 6FAM- CAG CAC CTT CCG TCT TT –MGBNFQ 49–65
HPRT1 Forward 59- AGG TGT TTA TTC CTC ATG GAC TAA TTA TGG -39 1–30
(EF078978) Reverse 59- CAC CCA TCT CCT TCA TCA CAT CTC -39 52–75
Probe 6FAM- ACA GGA CCG AAC GAC TG –MGBNFQ 31–47
RPL19 Forward 59-CAA AAA CAA GCG GAT TCT CAT G -39 340–361
(AY158223.1) Reverse 59- GCT TCT TGC GAG CCT TGT CT -39 385–404
Probe 6FAM- AAC ATA TCC ACA AGC TGA A –MGBNFQ 363–381
18S Eukaryotic 18S rRNA endogenous VIC/MGB Probe and Primers (Applied Biosystems, Foster City, CA, USA)
doi:10.1371/journal.pone.0037899.t001
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actin; cyclophilin A; HPRT1; YWHAZ; 18s, and RPL19) were
screened for stable expression. Stability of expression was
evaluated by inspection of the standard deviation (SD) and
coefficient of variance (CV) calculated for each HKG across
a range of samples. HKGs were ordered from the most stably
expressed (exhibiting the lowest variation) to the least stable one.
The geometric mean of the three most stably expressed HKGs
(cyclophilin A, GAPDH, and RPL19) was calculated for each
sample to derive a Bestkeeper index as described by Pfaffl et al
[36]. Real time PCR amplification efficiencies were calculated
from the slopes of the standard curves for each target gene and
HKG. Gene expression levels were expressed relative to the
control or saline groups and as a ratio to HKG mRNA levels using
a mathematical model; this model incorporates the efficiency of
amplification for each individual transcript, thereby accounting for
any variation in amplification efficiency amongst transcripts [37].
Oligonucleotide primers and probes
Ovine sequences in GenBank for the target genes were analysed
using Primer Express Software (Applied Biosystems) to determine
optimum minor groove binding primer and probe locations
(Table 1). A BLAST search ensured that primers and probes were
not designed from homologous regions that would encode for
proteins other than our target proteins. For mTOR and SLC38A4,
ovine sequences were not available and bovine sequences were
used, selecting the regions that were maximally conserved across
different mammalian species.
Protein extraction and quantification
We were unable to identify a suitable antibody against SLC2A3.
For trans-membrane SLC2A1 and SLC2A4 molecules, protein
was extracted on ice with 0.5 ml lysis buffer (150 mM NaCl,
50 mM Tris pH 6.8, 1 mM ethylene diamine tetraacetic acid
(EDTA), 1 mM ethylene glycol tetraacetic acid (EGTA), 2 mM
sodium orthovanadate). Tissue samples were homogenized for 15–
20 s and centrifuged at 700 rcf for 5 min at 4uC. Supernatants
were transferred to fresh tubes and pellets were re-suspended in
0.5 ml lysis buffer (2% triton X-100, 1% sodium deoxycholate and
1% sodium dodecyl sulphate, 150 mM NaCl, 50 mM Tris pH 6.8,
1 mM EDTA, 1 mM EGTA, 2 mM sodium orthovanadate).
Samples were re-homogenized for 15–20 sec, left on ice for a few
minutes and were then transferred back into tubes containing its
supernatant. Lysates were then rotated for 30 min at 4uC. Lysates
were stored at 280uC.
For mTOR, a cytosolic protein, this protocol was modified to
use: 1 ml of lysis buffer (20 mM Tris (pH 7.5), 150 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1% Triton X-100, Complete Mini
protease inhibitor cocktail (Roche Diagnostics GmbH, Mannheim,
Germany) and phosSTOP phosphatase inhibitor cocktail (Roche)).
Tissue samples were then homogenized for 15–20 s and centri-
fuged at 16,100 rcf for 15 min at 4uC, and supernatant were
transferred into fresh tubes to be stored at 80uC.
Protein content of all lysates was determined using a modified
Lowry method (Bio-Rad DC-protein assay kit, Bio-Rad Labora-
tories, Inc, Hercules, CA, USA).
Western blotting
Western blots for SLC2A1 and SLC2A4 were performed using
pre-cast NuPAGEH 4–12% Bis-Tris Gels (Invitrogen, Carlsbad,
CA, USA). The loading samples, containing protein lysate, MilliQ
water, 1 M DTT (final concentration 100 mM) as a reducing
agent, and 4 x NuPAGE loading dye (Invitrogen) in a total volume
of 40 ml, were prepared on ice and then heated at 70uC for
10 min. 30 ml of sample containing 60 mg of protein and 8 ml lane
marker (SeeBlue plus2 pre-stained standard; Invitrogen) were
loaded into each well. An identical reference sample was included
in each gel to account for inter-gel variability.
Gels were run at 200 V for 50 min with NuPAGEH MOPS (3-
(N-morpholino) propanesulphonic acid) running buffer. 500 mlo f
NuPAGE antioxidants (Invitrogen) were added to the inner
chamber. Proteins were transferred on to PVDF membranes using
iBlotTM Gel Transfer Stack and iBlotTM Dry Blotting System
(Invitrogen). Membranes were air-dried, soaked in methanol
solution, rinsed with MilliQ water, and left with blocking buffer
(5% non-fat dry milk, 1x PBS +0.1% Tween 20) at 4uC overnight
on a shaker.
Membranes were washed with 1x PBS +0.1% Tween before
incubation for 2 h at room temperature with primary antibodies
(SLC2A1: dilution 1:5,000, catalogue number ab32551; SLC2A4:
1:2,000, ab37445; beta actin: 1:200,000, ab6276; all Abcam plc,
Cambridge, UK,). Following four 5 min washes with 1x PBS
+0.1% Tween, membranes were incubated with secondary
antibody (A0545, Sigma Aldrich, MO, USA 1:10,000, for GLUTs;
A9044, Sigma Aldrich 1:200,000, for b-actin) for one hour at
room temperature.
For mTOR (MW ,289 kDa) the Western blot protocol was
modified to include use of NuPageH Tris-Acetate running buffer,
Hi Mark Pre-stained protein standard and NuPageH Novex 3–8%
Tris-Acetate Gel (all Invitrogen) for gel electrophoresis. 80 mg total
protein were added per lane and gels were run for 1 h at 150 V.
Gels were then incubated in 2x NuPageH transfer buffer contain-
ing 10% methanol and 1:1,000 antioxidant for 10 min. After
transfer, membranes were blocked at room temperature for 3–4 h,
then incubated overnight at 4uC with primary antibody (mTOR
(#2972) and phospho-mTOR (#2971S), Cell Signaling, Danvers,
MA, USA; both 1:10,000 dilution) in PBS-Tween containing 5%
bovine serum albumin.
Following incubation with secondary antibody, membranes
were washed five times for 5 min with 1x PBS +0.1% Tween and
then incubated for 5 min with enhanced chemiluminescence
detection substrate (SuperSignalH West Dura Extended Duration
Substrate kit, Pierce Biotechnology Inc, Rockford, IL, USA).
Bands were visualized by exposure to autoradiographic film
(AGFA, Gevaert, Belgium). Densitometric analysis was performed
on a GS800 Calibrated Densitometer (Bio-Rad, Hercules, CA,
USA) using the Quantity One Software (Bio-Rad), with all data
normalised to the relative optical density of the beta actin band.
Molecular weights of proteins
The SLC2A1 protein detected by SLC2A1 antibody yielded
single bands of ,61 kDa molecular weight. The specificity of
antibody was tested using rat liver tissue as a positive control with
an observed band of ,30 kDa. The observed bands of SLC2A4
for sheep tissue were at , 30 kDa molecular weight, for beta actin
were at ,45 kDa, and for mTOR and p-mTOR at ,289 kDa.
Data analysis
Blood oxygen content was calculated from measured hemoglo-
bin, oxygen saturation, and PaO2 [38]. Uptakes of oxygen,
glucose, and lactate were calculated for the uterus and its contents
[35]. Uterine and umbilical blood flows were calculated from
steady-state antipyrine diffusion [35]. Clearances of 3-O-[Me
3H]-
glucose and [
14C]urea were calculated using steady-state diffusion
techniques [35]. Fetal urea production rate was calculated as the
product of [
14C]urea clearance and the (fetal artery – maternal
artery) urea concentration difference [35].
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and analyzed separately for embolization (103–110 dGA) and
treatment (110–131 dGA) periods. A general linear model was
used with girth increment as the response variable, and treatment
group and dGA as the independent variables, with dGA also
included as a covariate. All other analyses used similar models
except that dGA was included only as a covariate. Fetal size and
organ weights were analysed by ANOVA, with Tukey’s post hoc
comparisons. SLC2A1, SLC2A4, mTOR and p-mTOR western
blots were analysed using Kruskal-Wallis tests in JMP (v. 7.0; SAS
institute Inc, Cary, NC, USA). All other analyses were carried out
in Minitab (v.15, Pennsylvania State University, USA), with
Johnson transformation as required to stabilize the variance. Data
are mean6SEM or fold change (95% confidence intervals), as
appropriate.
Results
Forty-two singleton-bearing ewes (17 Control, 14 IUGR, 11
IGF1) started the experiment, and 38 (15, 12, and 11, respectively)
reached the treatment phase. All data are not available for all
animals due to fetal losses, catheter failures, or insufficient
quantities of fetal plasma for analysis.
Fetal growth, body and organ size
Fetal hind limb length and chest girth at surgery were not
different amongst groups (hind limb length: Control,
17.461.0 mm; IUGR, 18.561.4 mm; IGF1, 16.561.5 mm;
Chest girth: Control, 22.860.4; IUGR, 22.560.7 mm; IGF1,
21.460.6 mm). However, IGF1 fetuses had smaller biparietal
diameters than IUGR fetuses (p,0.05) at surgery (Control,
49.060.6 mm; IUGR, 50.060.9 mm; IGF1 46.760.9 mm).
Embolization reduced fetal growth rate compared with control
fetuses (p,0.05; Fig. 1). During the treatment period, growth rate
of IGF-1-treated fetuses was greater than saline-treated fetuses
(p,0.01; Fig. 1), and not different from controls. At post mortem,
saline-treated fetuses were 21% lighter, and had shorter crown-
rump, limb lengths, and chest girth than controls (Table 2).
Total placental weight was reduced in IUGR fetuses compared
with controls (Table 2); IGF1 placental weight was not significantly
different from either Control or Saline. Both IUGR and IGF1
animals tended to have decreased placentome number and
average placentome weight compared with controls, but these
differences were not statistically significant (Table 2). Absolute fetal
lung, thymus, and spleen weights were also markedly reduced in
saline-treated fetuses; thymus and spleen weights remained
reduced when corrected for body weight. In contrast, relative
brain, kidney, adrenal, and peri-renal fat weights were increased
compared with controls (Table 2). IGF-1-treated fetuses were not
Figure 1. Fetal growth rate presented as the increase in girth
size (mm) relative to the starting date of measurements (101
dGA). Data points are the means with SEM. Emb marks the start of the
embolization period, which is indicated by the horizontal gray bar. At
T1, T2 and T3 the IUGR and IGF1 groups received intra-amniotic saline or
IGF-1 injections, respectively. * p,0.05 and ** p,0.01 for IUGR vs.
Control; { p,0.05 for IGF1 vs. Control; ¥¥ p,0.01 for IGF1 vs. IUGR.
doi:10.1371/journal.pone.0037899.g001
Table 2. Fetal body measurements at postmortem (131 dGA).
Control IUGR IGF1
Absolute Weight (g)
Fetal weight 38956206 30876280* 32186261
Adrenals 0.560.1 0.660.1 0.660.2
Brain 44.561.7 41.362.0 42.362.1
Heart 29.361.3 26.760.2 26.162.5
Kidneys 26.362.0 26.862.6 26.462.2
Liver 145.3614.1 123.9616.4 112.6610.9
Lungs 117.667.2 85.266.8** 99.064.9
Pancreas 3.660.3 3.060.3 3.360.4
Perirenal fat 12.660.8 13.762.8 13.160.8
Spleen 11.460.2 6.661.3* 6.560.6*
Thymus 15.161.9 8.061.9* 11.362.7
Thyroid 1.060.2 0.960.2 0.960.2
Uterus 706633 596657 613660
Placenta 596.0692.6 340.1641.4* 395.0644.8
Placentome number 78656 4 656 9 65
Mean placentome
weight
6.0460.79 4.1060.84 4.3660.90
Fetal: placental
weight ratio
8.0460.77 9.2860.77 8.5160.87
Relative Weight (g/kg body weight)
Adrenals 0.1260.02 0.2060.03* 0.1860.02
Brain 11.660.5 13.860.7* 13.360.8
Heart 7.660.4 8.760.6 8.260.6
Kidneys 6.960.7 8.760.5* 8.460.6
Liver 38.064.1 40.464.3 35.562.5
Lungs 30.661.8 28.161.6 31.762.2
Pancreas 1.060.1 1.060.1 1.160.1
Perirenal fat 3.360.2 4.360.4* 4.260.3*
Spleen 3.060.5 2.060.2* 2.060.1
Thymus 3.860.3 2.460.4* 3.360.6
Thyroid 0.360.1 0.360.1 0.360.1
Length (cm)
CRL 43.961.0 40.661.0* 41.561.2
BPD 60.961.3 60.461.5 58.461.4
Chest (girth) 33.660.6 31.160.9* 31.660.8
Forelimb Hock-hoof 15.160.5 13.760.4* 14.060.6
Forelimb 27.860.4 25.660.7* 26.660.8*
Hindlimb Hock-hoof 17.960.3 16.560.3* 16.560.7*
Hindlimb 32.960.4 29.860.7** 30.561.2*
Values are mean6SEM. *p,0.05, **p,0.01 for comparison with Control.
Control (n=11), IUGR (n=9), and IGF1 (n=7).
doi:10.1371/journal.pone.0037899.t002
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the Control or saline-treated fetuses. However, IGF1 fetuses had
shorter limbs and lighter spleens than controls, as well as greater
relative peri-renal fat mass (Table 2).
Blood gas and metabolite concentrations
Embolization reduced fetal PaO2 and O2 content (Fig. 2), SaO2
(data not shown; p,0.001), and increased fetal hemoglobin
concentration compared with controls (Fig. 2). Fetal pH was
unaffected by embolization (data not shown), despite significantly
increased fetal plasma lactate concentrations (Fig. 3). Embolization
decreased fetal plasma concentrations of glucose (Fig. 3) and the
non-essential urea cycle amino acids arginine and ornithine
(Table 3). Fetal plasma concentrations of the essential amino acids
were not altered by embolization, but urea concentrations were
increased (p,0.05; Fig. 3) and taurine concentrations approxi-
mately doubled (Table 3).
There were no significant differences in maternal blood gas
variables or metabolites amongst groups during embolization
(Fig. 2, 3). However, maternal hemoglobin concentration
(p,0.05), PaO2 (p,0.05) and O2 content (p,0.05) were lower in
IGF1 group ewes than controls, and not significantly different
from saline-treated ewes (Fig. 2).
IGF-1 treatment had no significant effect on fetal blood gas and
metabolite concentration (Figs. 2, 3). In both embolized groups,
fetal plasma urea concentrations remained elevated (p,0.01) and
glucose concentrations depressed (p,0.01; Fig. 3). IGF-1 treat-
ment decreased fetal plasma concentrations of aspartate, histidine
and the branched-chain amino acids compared with saline-treated
fetuses, and increased tyrosine concentrations (Table 3).
IGF-1 treatment had no effect on maternal plasma metabolite
concentrations. However, maternal urea concentrations remained
significantly higher in both embolized groups compared with
controls (p,0.01; Fig. 3).
Placental function
Embolization considerably reduced uterine blood flow (Con-
trol=15446131, IUGR=9506161, IGF1=9476107 ml/
minNkg; p,0.05). Uterine uptake of glucose was significantly
reduced in saline fetuses compared with controls; IGF1 fetuses
were not significantly different from controls or saline fetuses
(Control=388638, IUGR=249628, IGF1=290632 mmol/
min; p,0.05). Embolization did not change clearance of 3-O-
[Me
3H]glucose (Control=3926185, IUGR=142640,
IGF1=182657 ml/minNkg; p=0.30) or urea (Control=50683,
IUGR=98621, IGF1=161644 ml/minNkg; p=0.48), and did
not change uterine uptakes of lactate and oxygen (data not shown).
Hormones
Embolization had no significant effect on IGF-1 concentrations
in maternal plasma or amniotic fluid, but reduced concentrations
in fetal plasma (p,0.001; Fig. 4). Amniotic fluid concentrations of
IGF-1 increased approximately 5-fold by three days after the first
IGF-1 injection (p,0.001), but were no longer different from
control and saline groups by the time of the second injection.
Thereafter, amniotic fluid IGF-1 concentrations remained higher
in IGF-1-treated animals (Fig. 4).
Fetal plasma IGF-1 concentrations remained significantly lower
than controls in both embolized groups during the treatment
period (p,0.001), and were unaffected by IGF-1 treatment (Fig. 4).
Maternal and fetal plasma cortisol concentrations were not
significantly different amongst groups throughout the experiment
(Fig. 4). However, embolization decreased maternal progesterone
concentrations (p,0.05), and these remained lower in both
embolized groups than in control ewes (p,0.01) throughout the
treatment period (Fig. 4).
Placental nutrient transporters
Embolization decreased placental mRNA levels of SLC2A1
compared with controls, but had no effect on SLC2A3 or SLC2A4
mRNA levels (Table 4). IGF-1 treatment increased SLC2A1 and
SLC2A4 mRNA levels compared with saline treatment (Table 4),
but did not affect SLC2A3. Placental SLC2A1 and SLC2A4
protein levels were not significantly different amongst groups
(Fig. 5). Embolization decreased placental mRNA levels of SLC7A1
and SLC7A8 by 31 and 38%, respectively, but had no effect on
SLC38A4 or SLC7A5 (Table 4). IGF-1 treatment increased mRNA
levels of placental SLC7A1 by 57%, SLC7A8 by 32%, and SLC38A4
by 500% compared with saline treatment (Table 4). Thus,
SLC38A4 mRNA levels were 5-fold higher in IGF1 fetuses than
in controls, although SLC7A1 mRNA levels were not significantly
different from controls (Table 4). SLC7A5 mRNA levels were not
altered by embolization or IGF-1 treatment (Table 4).
Placental mTOR
Embolization did not alter mRNA levels of mTOR (Table 4) or
protein levels of mTOR or phospho-mTOR compared with
controls (Fig. 5). IGF-1 treatment tended to increase mTOR
mRNA levels compared to IUGR (p=0.05 Table 4), but did not
change protein levels of total mTOR or its phosphorylated form
(p-mTOR; Fig. 5). The ratio of p-mTOR to total mTOR was 1.5-
fold greater in placentae from IGF-1-treated fetuses compared
with saline-treated IUGR fetuses (p=0.06; Fig 5).
Discussion
This study demonstrates that a once-weekly intra-amniotic
injection of a low dose of IGF-1 increases growth of ovine fetuses
with growth-restriction secondary to placental insufficiency. This
increased fetal growth is likely to be, at least in part, due to
increased expression of placental amino acid transporters medi-
ated by mTOR. These findings suggest a potential approach to
intrauterine treatment of fetal growth restriction that may be
clinically acceptable.
Fetal plasma IGF-1 concentrations were unaltered with weekly
intra-amniotic IGF-1 treatment, consistent with findings following
thrice-weekly treatment with 120 mg IGF-1 [18]. In contrast, daily
administration of IGF-1 (20 mg/dose) for ten days significantly
reduced fetal plasma IGF-1 concentrations [19]. These consistent
findings of unchanged or decreased plasma IGF-1 concentrations
with a variety of intra-amniotic treatment regimens suggests the
increased fetal growth rate following intra-amniotic IGF-1
treatment was not due to direct growth-promoting effects of
IGF-1, even though we have demonstrated previously that IGF-1
given into amniotic fluid is taken up intact across the fetal gut and
into the systemic circulation [17].
It is possible, however, that intra-amniotic IGF-1 stimulates fetal
nutrient uptake from amniotic fluid. Human studies suggest that
fetuses may obtain up to 15% of daily nitrogen requirements from
swallowed amniotic fluid [39,40]. We have previously demon-
strated that daily doses of intra-amniotic IGF-1 are swallowed by
the fetus [17], increase glutamine utilization by the fetal gut [34],
and restore the delayed gut development seen in IUGR fetuses
[19]. However, when we attempted to maximise the growth-
promoting effects of intra-amniotic IGF-1 by co-administering
additional nutrients to amniotic fluid, the effect of IGF-1 was
abrogated [18], suggesting that increased nutrient uptake across
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increase in fetal growth.
In IUGR secondary to placental insufficiency, the primary
problem is impaired fetal nutrient supply. In sheep, the acute
responses to a reduced supply of oxidative substrates are
mobilization of endogenous substrates and inhibition of protein
accretion. Amino acids from the carcass are mobilized, and
protein oxidation may account for up to 80% of oxygen
consumption in IUGR fetuses [41]. If the impaired nutrient
supply persists, amino acids appear to substitute glucose as the
major oxidative fuel, resulting in a 50% or greater increase in fetal
urea production [41].
Figure 2. Fetal and maternal arterial oxygen and hemoglobin concentrations. Data are means with SEM. Emb marks the start of the
embolization period, which is indicated by the horizontal gray bar. At T1, T2 and T3 the IUGR and IGF1 groups received either a saline or IGF-1 intra-
amniotic injection, respectively. Hb = hemoglobin.
*p,0.05 and
***p,0.001 for IUGR vs. Control;
{p,0.05,
{{p,0.01 and
{{{p,0.001 for IGF1 vs.
Control.
doi:10.1371/journal.pone.0037899.g002
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the current study are consistent with this response. The amino
acids utilized by the fetus could arise either from increased
transport across the placenta, or from breakdown of fetal tissue.
Our finding of increased plasma concentrations of branched-chain
amino acids (BCAA) in IUGR fetuses is consistent with muscle
breakdown. In the placental specific igf2 knockout mouse,
a compensatory increase in amino acid and glucose transport
across the placenta occurs prior to the onset of IUGR. Failure of
this compensation appears to precede the onset of fetal growth
restriction [42].
Figure 3. Fetal and maternal plasma metabolite concentrations. Data are means with SEM. Emb marks the start of the embolization period,
which is indicated by the horizontal gray bar. At T1, T2 and T3 the IUGR and IGF1 groups received either a saline or IGF-1 intra-amniotic injection,
respectively.
*p,0.05,
**p,0.01 and
***p,0.001 for IUGR vs. Control;
{p,0.05,
{{p,0.01 and
{{{p,0.001 for IGF1 vs. Control.
doi:10.1371/journal.pone.0037899.g003
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transport may precede the onset of IUGR [25], and have reported
down-regulation of amino acid transporter activities in IUGR
placentae [43]. Consistent with these data, we found decreased
SLC7A1 and SLC7A8 mRNA levels in IUGR placentae. However,
SLC38A4 and SLC7A5 mRNA levels were not altered, which may
reflect different timings in the failure of compensation for different
amino acid transporters. Alternatively, these mRNA levels reflect
expression in whole placentomes, meaning that differential
regulation of amino acid transporters on the maternal and fetal-
facing membranes may be masked. Further, amino acid trans-
porter activity may also be altered without changes in gene
expression due to post-translational or conformational changes
[44].
An alternative possible mechanism for the growth-promoting
effects of IGF-1 in this study may be effects on the placenta, via
either increased blood flow or increased placental nutrient
transport. IGF-1 has vasodilatory effects that are mediated by
nitric oxide [45]. However, attempts to improve uterine artery
blood flow by administration of nitric oxide donors to the mother
have not been effective [13,14], and we did not find an effect of
IGF-1 treatment on uterine blood flow. Although we have
previously demonstrated that a continuous intravenous infusion
of a similar daily dose of IGF-1 to the fetus alters placental
clearance of glucose and amino acid analogues [19,35], there was
no effect of intra-amniotic IGF-1 on glucose uptake across the
placenta in this study.
However, weekly intra-amniotic IGF-1 treatment did result in
significant up-regulation of mRNA levels of placental transporters
for neutral (SLC38A4), cationic (SLC7A1), and branched-chain
amino acids (SLC7A8), which could provide a mechanism for
increased substrate supply to the IUGR fetus. To our knowledge
SLC38A4 has not been studied in the sheep placenta before,
although expression in a variety of bovine tissues has been
reported [46]. It is an isoform of system A found in both the basal
and microvillous membranes of the human placenta [47], and is
also found in the bovine placental caruncle [46]. SLC38A4
transports neutral amino acids with small side chains (e.g. alanine,
glycine, and glutamine) in a sodium- and pH-dependent manner,
and cationic amino acids (e.g. arginine and lysine) in a sodium-
and pH-independent manner. The system L transporter (SLC7A5
and SLC7A8) carries neutral amino acids with large and branched
Table 3. Fetal plasma concentrations of essential and non-essential amino acids during the embolization and treatment periods.
Embolization Treatment
Control
(n=10)
IUGR
(n=6)
IGF1
(n=9)
Control
(n=5)
IUGR
(n=4)
IGF1
(n=6)
ESSENTIAL
Isoleucine 98.168.6 104.968.9 83.867.6 86.666.1 94.566.3 76.763.8
Leucine 157.8610.3 168.1613.3 137.469.7 134.668.6 159.6612.9 130.865.5
Lysine 98.967.9 91.9626.7 92.267.0 89.6611.0 85.568.0 89.366.9
Methionine 26.262.8 30.064.3 30.263.6 23.062.0 30.263.9 25.162.8
Phenylanine 81.467.3 86.968.7 94.267.3 80.665.8 87.765.1 81.264.4
Threonine 319.3628.8 245.7625.3 264.8638.6 329.7635.0 266.2618.7 256.2634.4
Valine 435.5628.4 468.8649.8 374.3633.3 385.0621.9 462.0626.7 374.5618.1{
BCAA 691.4645.5 741.8668.1 565.9643.7 606.2635.7 716.1644.6 582.1626.4{
NON-ESSENTIAL
1-methylhistidine 3.560.5 2.160.4 2.760.3 3.760.4 3.660.7 3.660.6
3-methylhistidine 32.365.3 24.663.4 25.264.2 30.865.2 41.966.1 30.365.1
Alanine 227.2612.6 267.9624.1 239.5617.8 232.2613.3 291.2618.4 252.9621.5
Arginine 83.965.0 52.064.6** 62.765.2* 79.666.4 68.265.7 74.964.0
Asparagine 50.764.2 52.665.5 49.164.1 42.262.7 54.664.0* 43.663.0
Aspartate 7.160.7 7.661.4 6.060.6 6.560.5 7.960.9 5.860.4{
Citrulline 193.7613.1 157.768.0 178.1614.2 182.5613.2 169.866.2 212.6614.3
Glutamine 405.9625.0 410.9632.4 401.1634.8 363.0619.3 448.6626.5 380.9627.3
Glutamate 45.163.9 35.867.5 32.263.1 42.063.4 41.864.6 38.463.4
Glycine 305.1629.5 293.3612.8 269.5614.3 279.4622.0 294.4614.3 265.7618.9
Histidine 25.062.1 25.163.5 26.362.0 22.661.8 34.762.9** 25.862.4{
Hydroxyproline 44.463.9 45.663.6 44.463.2 44.362.6 54.764.1 47.363.0
Ornithine 71.666.1 44.564.9** 50.164.5* 60.564.0 52.064.0 57.365.2
Proline 147.3612.1 193.5624.8 173.7624.3 134.2610.8 164.664.6 156.2610.2
Serine 422.3649.1 488.4661.8 400.4657.0 424.9651.6 575.1655.1 437.3651.2
Taurine 90.7618.0 201.0631.6* 175.5629.9* 86.4616.4 160.6633.5 236.06103.0
Tyrosine 108.6612.5 90.7613.1 137.3625.7 113.569.2 83.365.4 121.368.8{
Values are mean6SEM (mMol/L). *p,0.05 and **p,0.01 for comparison with Control, while {p,0.05 for comparison with IUGR.
doi:10.1371/journal.pone.0037899.t003
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SLC7A1, an isoform of system y+, the major cationic amino acid
transporter in the placenta [48], transports amino acids such as
lysine and arginine. Our data demonstrate considerable up-
regulation (between 132 and 500%) of isoforms of all three amino
acid transporter systems studied, suggesting that effects of IGF-1
on the placental may explain the increased fetal growth seen.
Functional studies of amino acid uptake are required to verify this.
IGF-1 has been reported to increase placental system A activity
and expression in cultured human trophoblast cells and in BeWo
choriocarcinoma cell lines [26,49]. The role of IGF-1 in regulation
of system y+ transporter expression is poorly understood, but may
be similar to that described for system A.
Increased transplacental transport of other amino acids,
mediated by the increased levels of SLC38A4, SLC7A1, and
SLC7A8, may have decreased the need for fetal muscle breakdown
Figure 4. Hormone concentrations in fetal plasma, maternal plasma and amniotic fluid. Data are means with SEM. Emb marks the start of
the embolization period, which is indicated by the horizontal gray bar. At T1, T2 and T3 the IUGR and IGF1 groups received either a saline or IGF-1
intra-amniotic injection, respectively.
*p,0.05 and
***p,0.001 for IUGR vs. Control;
{{p,0.01 and
{{{p,0.001 for IGF1 vs. Control;
¥¥¥p,0.001 for IGF1
vs. IUGR.
doi:10.1371/journal.pone.0037899.g004
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placental glucose metabolism and conserving other metabolic fuels
for the fetus [34]. This is supported by the observed decrease in
plasma BCAA concentrations in IGF-1 treated fetuses.
Activity of the placental amino acid transporters in the human
placenta is mediated by mTOR [25,51]. Upstream regulators of
mTOR activity in trophoblast cells include glucose concentrations,
BCAA concentrations, insulin, and IGF-1 [51,52]. mTOR is
activated by phosphorylation at Ser
2448, and placental expression
of p-mTOR may be a more reliable indicator of mTOR activity
[53]. Placental total mTOR protein has been reported to be
decreased in human IUGR [54,55] and in rat pregnancies
subjected to protein undernutrition [56], although it has also been
reported to increase in an ovine paradigm of IUGR [57]. There
are few data on the interactions between the mTOR and IGF-
AKT signaling pathways in the placenta. However, in other
tissues, the close integration of these pathways with the p53
pathway in the sensing of nutrient and growth factor availability is
well described, as well as the subsequent transduction of these
signals into cell growth and proliferation [58]. Nonetheless, in
human trophoblast cells, the up-regulation of system A activity by
IGF-1 has been shown to be mediated via increased mTOR
activity [51]. We found that mRNA and protein levels of both total
mTOR and p-mTOR were unchanged in IUGR fetuses. IGF-1
treatment resulted in an increase in mRNA levels of mTOR of
borderline statistical significance (p=0.05), with a p-mTOR:m-
TOR ratio that tended to be greater than in saline-treated IUGR
fetuses (p=0.06). Although our data on the effect of IGF-1 on
mTOR are not conclusive, they do suggest that further in-
Table 4. mRNA levels for candidate genes in the placenta.
Relative Expression
Ratio (95% CI)
IUGR:
Control
IGF1:
Control
IGF1:
IUGR
System A:
SLC38A4
1.06 (0.65–1.71) 5.30 (2.77–10.1)* 5.0 (2.35–10.7)*
System y+:
SLC7A1
0.62 (0.58–0.66)* 0.96 (0.61–1.52) 1.57 (1.07–2.28)*
System L:
SLC7A5
1.06 (0.82–1.38) 0.92 (0.47–1.80) 0.87 (0.41–1.82)
System L:
SLC7A8
0.69 (0.62–0.77)* 0.91 (0.68–1.21) 1.32 (1.11–1.57)*
SLC2A1 (GLUT1) 0.67 (0.62–0.71)* 1.03 (0.69–1.43) 1.50 (1.12–2.01)*
SLC2A3 (GLUT3) 1.01 (0.85–1.17) 1.06 (0.69–1.51) 1.03 (0.72–1.46)
SLC2A4 (GLUT4) 0.84 (0.63–1.12) 1.12 (0.93–1.35) 1.33 (1.02–1.74)*
mTOR 0.96 (0.85–1.08) 1.27 (0.94–1.70) 1.32 (1.00–1.75)
{
Data are fold change (95% CI) relative to the control or IUGR group expressed as
a ratio to the Bestkeeper index derived from three housekeeping genes
(cyclophilin A, GAPDH and RPL19) [36,37]. First column: IUGR group compared
with control; middle column: IGF1 group compared with Control; last column:
IGF1 group compared with IUGR. Where 95% confidence intervals do not cross
1 the two groups are significantly different at the 5% level (shown by *, with
{representing p=0.05). Control (n=11), IUGR (n=9), and IGF1 (n=7).
doi:10.1371/journal.pone.0037899.t004
Figure 5. Placental protein levels of glucose transporters 1 and 4 and mammalian target of rapamycin (mTOR). [A] SLC2A1 (GLUT1), [B]
SLC2A4 (GLUT4), [C] total mTOR, [D] phosphorylated mTOR (phospho-mTOR), and [E] the ratio of phospho-mTOR to total mTOR. Data are relative
optical densities (ROD, mean6SEM) of the protein of interest normalised to the ROD of the loading control (beta-actin). Black bar, control, n=11;
white bar, IUGR, n=9; grey bar, IGF1, n=7. Complete gels are shown, with all four gels for SLC2A1 and SLC2A4 and representative gels for mTOR and
phospho mTOR.
{p=0.06 compared with IUGR.
doi:10.1371/journal.pone.0037899.g005
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effects we report is warranted.
Embolization and IUGR also decreased mRNA levels of
SLC2A1 in IUGR placentae, consistent with the decreased uterine
glucose uptake that we report. However, the decreased SLC2A1
mRNA levels were not matched by a significant up-regulation in
GLUT-1 protein expression, presumably due to inadequate
sensitivity of the Western blotting technique to post-translational
changes [59], or to the fact that we measured protein levels of
membrane-bound GLUT-1 that may not reflect total protein in
the cell. We could not study placental GLUT-3 expression because
of the unavailability of a suitable antibody, but we provide the first
evidence for the presence of GLUT-4 in the ovine placenta.
GLUT-4 has been reported in rodent and human placentae,
predominantly in early gestation [22,23] but also at term [60,61].
There are few data on GLUT-4 regulation in response to an
adverse fetal nutritional environment, but levels were not reported
to change in rabbit pregnancies complicated by maternal
hypercholesterolemia [61], or in a small number of human term
placentae from pregnancies complicated by IUGR or maternal
diabetes [60].
The effect of IGF-1 on placental GLUT expression in IUGR
placentae has not been reported previously. We found that IGF-1
treatment of IUGR fetuses increased placental SLC2A1 and
SLC2A4, but not SLC2A3 mRNA levels, and also did not change
placental GLUT-1 and GLUT-4 protein levels. Further, IGF-1
treatment did not affect fetal blood glucose concentrations or
placental glucose uptake, although the decreased uterine uptake of
glucose seen in IUGR animals was partially reversed with IGF-1
treatment. Thus, increase in mRNA levels of SLC2A1 and SLC2A4
with IGF-1 treatment may not reflect similar changes in activity.
In conclusion, this study demonstrates that weekly intra-
amniotic IGF-1 injections increase fetal growth trajectory without
apparent adverse effects on the fetus. In particular, fetal blood
oxygen content is maintained. Furthermore, IGF-1 treatment up-
regulates mRNA levels of placental transporters for neutral,
cationic, and branched-chain amino acids, possibly via increased
activation of the mTOR pathway. This may be a mechanism for
increased substrate supply to IUGR fetuses, explaining the
observed increase in fetal growth. A once-weekly intrauterine
therapy for the IUGR fetus could be of clinical utility if the
benefits outweighed the risks. However, although we have
reproducibly demonstrated a positive effect of intra-amniotic
IGF-1 treatment in growth-restricted fetal sheep, there are no data
on postnatal outcomes, either short-term or long-term. Future
studies should address critical postnatal outcomes such as perinatal
morbidity and mortality, as well as long-term outcomes, including
somatotrophic axis function and body composition.
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